Biopharma CRO industry in China: landscape and opportunities.
作者： Christine Xia , Ajay Gautam
DOI: 10.1016/J.DRUDIS.2015.02.007
关键词:
摘要: The pharmaceutical industry has responded to the declining research and development (RD approximately 60% of companies were localized in Yangtze River Delta cluster another 20% within Beijing cluster. Almost 25% offered services discovery biology, single largest service offering data set, with preclinical (toxicology, pharmacology, animal models) 15% development. biologics represent key future growth areas, CROs showing an increasing appetite for risk-sharing partnerships.
core.ac.uk
elsevier.com
sci-hub.se 参考文章(4)
Simon Goodall, Bart Janssens, Kim Wagner, John Wong, Wendy Woods, Michael Yeh, The promise of the East: India and China as R&D options. Nature Biotechnology. ,vol. 24, pp. 1061- 1064 ,(2006) , 10.1038/BIOENT910
Ajay Gautam, Steve Yang, A framework for biomedical innovation in emerging markets Nature Reviews Drug Discovery. ,vol. 13, pp. 646- 647 ,(2014) , 10.1038/NRD4413
Ish Khanna, Drug discovery in pharmaceutical industry: productivity challenges and trends Drug Discovery Today. ,vol. 17, pp. 1088- 1102 ,(2012) , 10.1016/J.DRUDIS.2012.05.007
Simon P. Forster, Julia Stegmaier, Rene Spycher, Stefan Seeger, Virtual pharmaceutical companies: collaborating flexibly in pharmaceutical development. Drug Discovery Today. ,vol. 19, pp. 348- 355 ,(2014) , 10.1016/J.DRUDIS.2013.11.015